Yuhan expands the scope of non-small cell lung cancer to be applied to the third-generation new drug ‘Rexraza’
2023-07-01 11:39:56 Rexraza, developed by Yuhan Corporation, has been approved by the Ministry of Food and Drug Safety as a first-line treatment for epidermal growth